Bernard L A, Bergman J N, Eichenfield L F
Pediatric and Adolescent Dermatology, Childrens' Hospital and Health Center, San Diego, CA, USA.
Skin Therapy Lett. 2002 Apr;7(4):1-3.
Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases. Phase II and III clinical trials with the topical formulation of pimecrolimus (Elidel cream, Novartis) have shown that it is safe and effective for use in patients with atopic dermatitis (AD). The US FDA recently approved Elidel for use in patients >or=2 years of age and older with mild to moderate atopic dermatitis (AD).
吡美莫司是一种免疫调节药物，可抑制皮肤中炎性细胞因子的产生，该化合物是专门为治疗炎性皮肤病而研发的。吡美莫司局部制剂（爱宁达乳膏，诺华公司）的II期和III期临床试验表明，它用于特应性皮炎（AD）患者是安全有效的。美国食品药品监督管理局最近批准爱宁达用于≥2岁的轻度至中度特应性皮炎（AD）患者。
